Track topics on Twitter Track topics that are important to you
Foamix Pharmaceuticals intends to market its acne treatment by itself.
Foamix Pharmaceuticals has completed patient enrolment and dosing in the FX2016-11 and FX2016-12 studies designed to treat moderate-to-severe papulopustular rosacea....Read More... The post Foamix com...
Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.
Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading. ...
Israel's Foamix has said it is planning a US filing of its minocycline-based topical acne treatment after positive late stage trial results. The third phase 3 trial of FMX101, a topical minocycline ...
Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of activ...
We have published hundreds of Foamix Ltd news stories on BioPortfolio along with dozens of Foamix Ltd Clinical Trials and PubMed Articles about Foamix Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foamix Ltd Companies in our database. You can also find out about relevant Foamix Ltd Drugs and Medications on this site too.
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...